Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
MRK Merck & Co., Inc. weekly Stock Chart
MRK [NYSE]
Merck & Co., Inc.
Healthcare | Drug Manufacturers - Major | USA
statements
IndexDJIA S&P500 P/E22.82 EPS (ttm)3.72 Insider Own0.08% Shs Outstand2.56B Perf Week1.57%
Market Cap217.17B Forward P/E15.11 EPS next Y5.62 Insider Trans-10.72% Shs Float2.54B Perf Month1.31%
Income9.67B PEG2.41 EPS next Q1.16 Inst Own78.00% Short Float0.78% Perf Quarter-1.50%
Sales45.97B P/S4.72 EPS this Y33.00% Inst Trans-0.73% Short Ratio2.45 Perf Half Y7.63%
Book/sh10.49 P/B8.09 EPS next Y8.77% ROA11.20% Target Price97.25 Perf Year14.59%
Cash/sh3.13 P/C27.09 EPS next 5Y9.47% ROE34.30% 52W Range70.89 - 87.35 Perf YTD11.11%
Dividend2.20 P/FCF63.76 EPS past 5Y10.60% ROI11.70% 52W High-2.80% Beta0.54
Dividend %2.59% Quick Ratio1.00 Sales past 5Y-0.80% Gross Margin70.50% 52W Low19.76% ATR1.44
Employees69000 Current Ratio1.30 Sales Q/Q14.90% Oper. Margin25.60% RSI (14)54.25 Volatility1.28% 1.86%
OptionableYes Debt/Eq0.97 EPS Q/Q1.50% Profit Margin20.30% Rel Volume1.10 Prev Close84.55
ShortableYes LT Debt/Eq0.84 EarningsOct 29 BMO Payout61.00% Avg Volume8.11M Price84.90
Recom1.80 SMA201.27% SMA501.39% SMA2003.46% Volume8,925,654 Change0.41%
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Nov-17-19 07:07AM  Hedge Funds Open Kimono: 5 Best Healthcare Stocks To Buy Insider Monkey
Nov-15-19 09:23AM  AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status Zacks
07:12AM  Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates Zacks
06:45AM  BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration Business Wire
06:41AM  4 Big Drugmakers to Bet on After a Great Earnings Season Zacks
05:33AM  Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings Bloomberg
Nov-14-19 05:26PM  Livongo Bounces Back After Revenue Guidance Boost GuruFocus.com
11:44AM  Cisco, Merck share losses lead Dow's nearly 75-point drop MarketWatch
09:44AM  FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes Zacks
09:44AM  Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
06:55AM  US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review Business Wire
02:19AM  Merck posts higher profit and revenue as it lifts sales forecast MarketWatch
02:10AM  UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover Reuters
01:22AM  Merck KGaA raises 2019 sales, earnings guidance in wake of Versum takeover Reuters
Nov-13-19 02:32PM  Ex-Novartis exec named as Flagship's matchmaker for Big Pharma partnerships American City Business Journals
10:51AM  Dow flat despite gains in Procter & Gamble, Coca-Cola shares MarketWatch
Nov-12-19 04:40PM  US Indexes End the Day Higher Tuesday GuruFocus.com
02:47PM  Should You Worry About Merck & Co., Inc.'s (NYSE:MRK) CEO Salary Level? Simply Wall St.
10:28AM  Dow's nearly 75-point climb highlighted by gains for shares of Merck, Walt Disney MarketWatch
09:00AM  NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®) GlobeNewswire
08:05AM  Merck's Ebola Vaccine Gets Conditional Approval in Europe Zacks
07:59AM  Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review Zacks
06:30AM  BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th GlobeNewswire
Nov-11-19 04:23PM  Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study Zacks
03:00PM  Mercks ERVEBO® Granted Conditional Approval in the European Union Business Wire
10:28AM  The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health Zacks
08:46AM  Novartis' Generics Unit to Buy Aspen's Japanese Operations Zacks
Nov-09-19 11:50AM  Quit being fooled by fast-growing companies claiming to be tech firms when they just use technology MarketWatch
Nov-08-19 03:06PM  Top Analyst Reports for Mastercard, UnitedHealth & Merck Zacks
12:20PM  Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y Zacks
10:04AM  The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co Zacks
Nov-07-19 03:37PM  Kahn Brothers' 3rd-Quarter Update GuruFocus.com
02:33PM  Teva climbs despite earnings miss Yahoo Finance Video
01:06PM  P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook Moody's
11:13AM  Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up Zacks
11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
09:17AM  Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks Zacks
06:44AM  UPDATE 1-Johnson & Johnson files for European approval of Ebola vaccine Reuters
05:00AM  Merck- Value Expert Eyes Pharma Favorite MoneyShow
Nov-06-19 03:22PM  Kahn Brothers Trims Merck, Exits Sterling Bancorp GuruFocus.com
08:00AM  NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-19 01:00PM  Value Biotech ETFs & Stocks to Buy Now Zacks
12:28PM  Marine algae keys Chinese claim to Alzheimers breakthrough MarketWatch
11:10AM  The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo Zacks
09:10AM  Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y Zacks
09:08AM  Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss Zacks
08:53AM  Merck Beats Earnings but Ends Week With 'Key Reversal' Investopedia
Nov-01-19 11:55AM  Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates Zacks
Oct-31-19 08:31PM  Edited Transcript of MRK earnings conference call or presentation 29-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
11:54AM  Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss Zacks
11:45AM  Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales Zacks
Oct-30-19 02:51PM  Johnson & Johnson, McDonald's share gains contribute to Dow's nearly 75-point climb MarketWatch
12:29PM  Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks
10:47AM  Stock Market News For Oct 30, 2019 Zacks
10:43AM  Healthcare ETFs Win in October: Here's Why Zacks
10:12AM  Merck loses bid to revive $2.54 billion patent verdict against Gilead Reuters
08:17AM  Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
07:23AM  GLOBAL MARKETS-Fed and $50bln auto merger plan temper share price pullback Reuters
Oct-29-19 06:10PM  US Indexes Close Lower Tuesday After 4-Day Rally GuruFocus.com
05:06PM  GLOBAL MARKETS-Stocks falter, dollar slips on potential U.S.-China trade delay Reuters
04:31PM  Dow Jones Today: Struggling at the Highs InvestorPlace
04:19PM  S&P 500 retreats from record high; Google miss weighs on tech shares MarketWatch
12:46PM  Why would the Fed cut interest rates a 3rd time in a row even as stocks near records? Investors may soon find out MarketWatch
12:01PM  Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings? Zacks
10:38AM  US STOCKS-S&P 500 flat on mixed earnings reports; Alphabet weighs on Nasdaq Reuters
10:38AM  Strong Q3 Earnings Data Deluge Zacks
10:30AM  Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View Zacks
10:26AM  Q3 Earnings Bonanza: GM, MRK, MA & More Zacks
10:12AM  Merck and Pfizer Stocks Are on a Roll as Earnings Beat Forecasts, Raise Hope About Big Pharma Barrons.com
10:06AM  A bear-market catalyst is lying in wait for stocks, warns UBS MarketWatch
10:00AM  Merck Hikes Forecast as Keytruda Tops $3 Billion for Quarter Bloomberg
09:51AM  Merck (MRK) Q3 Earnings and Revenues Surpass Estimates (Revised) Zacks
08:45AM  US STOCKS-Wall Street set for subdued open on mixed earnings reports Reuters
08:31AM  Merck, Pfizer stock gains on earnings beats would add 23 points to the Dow's price MarketWatch
08:15AM  Merck (MRK) Tops Q3 Earnings Estimates Zacks
07:48AM  US STOCKS-Futures tick lower on mixed earnings reports Reuters
06:57AM  Merck's stock rallies after profit and sales rise above expectations, full-year outlook raised MarketWatch
06:57AM  Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter Reuters
06:51AM  Merck quarterly profit falls on deal-related charge Reuters
06:45AM  Merck Announces Third-Quarter 2019 Financial Results Business Wire
04:22AM  Stocks - Pfizer, Merck Rise Premarket; Alphabet, Beyond Meat Tumble Investing.com
03:07AM  Merck Beats Q3 Profit Forecast, Boosts 2019 Guidance; Keytruda Sales Top $3 Bln TheStreet.com
02:50AM  U.S. Stock Futures Point to Slightly Lower Open With Earnings; Fed in Focus Investing.com
Oct-28-19 04:29PM  T Rowe Price Trims Microsoft, Exits Merck GuruFocus.com
02:00PM  European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma PR Newswire
12:25PM  UPDATE 2-AstraZeneca's combo drug for lung cancer succeeds in late-stage trial Reuters
12:04PM  Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings Zacks
11:59AM  Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More Zacks
11:06AM  Dow up 110 points on gains in shares of Microsoft, Goldman Sachs MarketWatch
10:19AM  Why Earnings Season Could Be Great for Merck (MRK) Zacks
08:40AM  Starbucks, Merck, and Cintas Are Expected to Raise Dividends This Week Barrons.com
07:48AM  Apple, Facebook and Exxon are about to lead a big test of the earnings recession MarketWatch
07:00AM  AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck Zacks Small Cap Research
Oct-26-19 06:00AM  Mercks Earnings Are on Tuesday. Heres What to Expect. Barrons.com
Oct-25-19 12:25PM  Zacks Value Trader Highlights: Merck, Disney, Whitestone REIT, Gap and Wells Fargo Zacks
Oct-24-19 02:04PM  Drugs, data and the darknet: Cybersecurity a growing threat in the life sciences American City Business Journals
12:15PM  Lessons on How to Build a Million Dollar Portfolio Zacks
10:25AM  Can Merck (MRK) Keep the Earnings Beat Streak Alive in Q3? Zacks
09:54AM  AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View Zacks
06:30AM  BriaCell Announces Voting Results of the Special Meeting of Shareholders GlobeNewswire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; 4D pharma plc; and Promega Corporation. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
open in yahoo | open in reuters | open in google